Expert: Elisa Gobbini, Gustave Roussy Institute, Villejuif, FR
Questions:
1-What is the role of immunotherapy in PD-L1 negative mNSCLC?
2-Could you describe the rational for cases with negative PDL1 responding to immunotherapy?
3-What about liquid PDL-1 assay and how to be implemented in clinical practice?
4-How long the duration required for re-exposition to previously received immunotherapy?
5-Patients with history of auto-immune diseases, there are any criteria to select the patient who will be candidate to receive immunotherapy or not?
